Inici › Leucèmia limfàtica crònica › Texas › Houston
Assaigs clínics de Leucèmia limfàtica crònica a Houston, TX
17 estudis de Leucèmia limfàtica crònica busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
ReclutantFase 1
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- UT MD Anderson Cancer Center, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
ReclutantFase 1/2
- Research Site, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
ReclutantFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ReclutantFase 3
- Md Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- The University of Texas MD Anderson Cancer Center, Houston
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ReclutantFase 2
- M D Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
ReclutantFase 1/2
- Research Site, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
ReclutantFase 1/2
- MD Anderson, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
ReclutantFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
ReclutantFase 2
- MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
ReclutantFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
ReclutantFase 1
- MD Anderson Cancer Center, Houston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
ReclutantFase 4
- University of Texas MD Anderson Cancer Center, Houston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
ReclutantFase 4
- University of Texas MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
ReclutantFase 1
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
Assaigs de Leucèmia limfàtica crònica en altres ciutats
- Boston, MA31 estudis
- Columbus, OH28 estudis
- Durham, NC27 estudis
- Washington, DC22 estudis
- Seattle, WA20 estudis
- Rochester, MN19 estudis
- New York City, NY18 estudis
- Baldwin Park, CA16 estudis
- Milwaukee, WI15 estudis
- Cincinnati, OH14 estudis
- Chicago, IL14 estudis
- Nashville, TN13 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.